Handok Inc., has contracted with Astellas Pharmaceuticals Inc. Korea (CEO, Dakenoya Osamu) for sales of SGLT-2-inhibitor-family diabetes treatment “Suglat Tab.” (ingredient name: ipragliflozin, hereinafter “Suglat”) in Korea. Handok Inc. will be in full charge of domestic distribution, marketing and sales activities of “Suglat.”

Through this contract, Handok Inc. has added the SGLT-2-inhibitor-family diabetes treatment Suglat to its existing list of diabetes drugs, which includes Amaryl (sulfonylurea family) and Tenelia (DPP-4 inhibitor family). Suglat is a diabetes treatment jointly developed by Astellas Pharmaceuticals Inc. and Kotobuki Pharmaceuticals in Japan. Suglat is the most prescribed drug among the SGLT-2-inhibitor-family diabetes treatments in Japan. The drug was launched in Korea in 2015.